在癌症患者中使用汇总的个人患者数据加速精确运动药物:POLARIS经验
Laurien M Buffart1,2, Marlou-Floor Kenkhuis1, Robert U Newton2
1Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.
JNCI cancer spectrum
|August 12, 2025
概括
针对癌症患者的精确运动药物显示了健康,疲劳和情绪方面的好处. 运动效果因患者特征和干预细节而异,指导个性化康复策略.
科学领域:
- 运动瘤学运动瘤学
- 癌症康复康复 癌症康复
- 精准医学是一门精准的医学.
背景情况:
- 许多运动瘤学试验为癌症患者的当前建议提供了信息.
- 针对癌症的运动药物可以根据类型,剂量,时间表和时间量身定制.
- 精确运动医学需要了解个体患者对干预措施的反应.
研究的目的:
- 突出聚合个人患者数据 (IPD) 分析的价值.
- 总结IPD对癌症患者运动效应的综合分析结果.
- 为推进瘤学中的精确运动医学提供指导.
主要方法:
- 使用了预测最佳癌症康复和支持性护理 (POLARIS) 研究基础设施.
- 从多个随机对照试验中对IPD进行了聚合分析.
- 包括52个运动试验中的IPD在当前的POLARIS数据库中.
主要成果:
- 在癌症患者中,运动干预有益于身体健康,疲劳,生活质量,认知,睡眠,焦虑和抑郁.
- 运动效应根据患者的特征 (例如,基线值,年龄,婚姻状况,教育程度) 进行修改.
- 干预特征 (如监督,特异性) 也会影响炼效应.
结论:
- 聚合IPD分析对于在癌症治疗中推进精确运动医学有价值.
- 未来的研究应该专注于研究不足的人群,临床结果,生物标志物和用于个性化治疗的机器学习.
- 根据个体患者和干预特征量身定制运动干预措施是最佳癌症康复的关键.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455


